GlassScriptPhysician profile
Amy B Berretta
NPI 1497110696
$7,135.04
in general payments reported to CMS, 2019-2025
23 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $954 · 2023: $1,126 · 2024: $2,227 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,837.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,297.63 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,259.69 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $982.30 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $541.98 | 2023-2025 | Auvelity |
| Corium, LLC | $304.79 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $299.29 | 2024-2025 | Qelbree |
| Alkermes, INC. | $296.24 | 2024-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $270.23 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $188.91 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $140.51 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $131.13 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $87.10 | 2022-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $63.12 | 2024-2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $52.82 | 2024-2025 | Spravato |
| Novo Nordisk INC | $52.07 | 2023-2025 | Wegovy, Saxenda |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $28.77 | 2022 | |
| Indivior INC. | $24.12 | 2023 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.33 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $21.93 | 2023 | |
| Antares Pharma, INC. | $21.23 | 2024 | Xyosted |
| Vanda Pharmaceuticals INC. | $18.98 | 2025 | Fanapt |
| Boston Scientific Corporation | $15.92 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.95 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Berretta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.